Clinical Trials Logo

Hemangioma, Capillary clinical trials

View clinical trials related to Hemangioma, Capillary.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02035319 Withdrawn - Port Wine Stain Clinical Trials

Effect of Laser Treatment on Capillary Malformations

Start date: January 2014
Phase: N/A
Study type: Observational

In this research study investigators want to learn more about capillary malformations which are also known as port wine stains. Investigators are asking children with capillary malformations (port wine stains) to be in the research, because investigators do not have a good idea of what to expect from the current treatments of these malformations. These malformations are treated with laser as clinically indicated and there are no standardized methods to assess improvement.

NCT ID: NCT01438047 Withdrawn - Port Wine Stain Clinical Trials

Optical Frequency Domain Imaging (OFDI) in Dermatology

Start date: September 2010
Phase: N/A
Study type: Observational

This is a pilot exploratory study. The goal of this study is to evaluate a new imaging tool, optical frequency domain imaging (OFDI), to reveal the microvascular morphology of capillary malformations.

NCT ID: NCT01408056 Withdrawn - Clinical trials for Infantile Hemangiomas

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

TOUCH
Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.

NCT ID: NCT01166919 Withdrawn - Port Wine Stain Clinical Trials

Pilot Study on the Use of the Matrix Radiofrequencyfor Treatment of Port Wine Stain Birthmarks

Start date: December 2009
Phase: Phase 1
Study type: Interventional

Port wine stain, also called nevus flammeus, is a congenital, cutaneous vascular malformation involving post-capillary venules which produces a light pink to red to dark-red-violet discoloration of the skin. It is estimated that Port wine stain occurs in 3 children per 1,000 live births. Approximately 900,000 individuals in the United States and twenty million people worldwide have Port wine stain birthmarks .

NCT ID: NCT00974129 Withdrawn - Hemangioma Clinical Trials

A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

Start date: September 2009
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.

NCT ID: NCT00969397 Withdrawn - Port Wine Stain Clinical Trials

Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The researcher want to improve port wine stain (PWS) therapeutic outcome in response to laser therapy. The researcher want to determine whether the combined use of pulsed dye laser (PDL) therapy and topical tacrolimus or pimecrolimus will improve PWS therapeutic outcome.

NCT ID: NCT00667472 Withdrawn - Port-Wine Stain Clinical Trials

Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Start date: March 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to improve port wine stain therapeutic outcome in response to laser therapy. The researcher want to determine whether the combined use of pulsed dye laser therapy and topical ranibizumab will improve port wine stain therapeutic outcome.

NCT ID: NCT00580944 Withdrawn - Port Wine Stain Clinical Trials

Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks

Start date: April 2007
Phase: Phase 1
Study type: Interventional

Port wine stain is a congenital, progressive vascular malformation of skin involving post-capillary venules that occurs in an estimated 4 children per 1,000 live births. Approximately 1,200,000 individuals in the United States and twenty-six million people worldwide have Port wine stain birthmarks. Since most of the malformations occur on the face, Port wine stain is a clinically significant problem in the majority of patients. Port wine stain should not be considered a cosmetic problem but a disease with potentially devastating psychological and physical complications. Personality development is adversely influenced in virtually all patients by the negative reaction of others to a "marked" person. Port wine stain are initially flat red macules, but lesions tend to darken progressively to purple, and by middle age, often become raised as a result of the development of vascular nodules. Hypertrophy of underlying soft tissue further disfigures the facial features of many patients.